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Routine childhood immunisation during the COVID-19 
pandemic in Africa: a benefit–risk analysis of health benefits 
versus excess risk of SARS-CoV-2 infection
Kaja Abbas*, Simon R Procter*, Kevin van Zandvoort, Andrew Clark, Sebastian Funk, Tewodaj Mengistu, Dan Hogan, Emily Dansereau, Mark Jit, 
Stefan Flasche, LSHTM CMMID COVID-19 Working Group†
Summary
Background National immunisation programmes globally are at risk of suspension due to the severe health system 
constraints and physical distancing measures in place to mitigate the ongoing COVID-19 pandemic. We aimed to 
compare the health benefits of sustaining routine childhood immunisation in Africa with the risk of acquiring severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through visiting routine vaccination service delivery 
points.
Methods We considered a high-impact scenario and a low-impact scenario to approximate the child deaths that could 
be caused by immunisation coverage reductions during COVID-19 outbreaks. In the high-impact scenario, we used 
previously reported country-specific child mortality impact estimates of childhood immunisation for diphtheria, 
tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Streptococcus pneumoniae, rotavirus, measles, meningitis 
A, rubella, and yellow fever to approximate the future deaths averted before 5 years of age by routine childhood 
vaccination during a 6-month COVID-19 risk period without catch-up campaigns. In the low-impact scenario, we 
approximated the health benefits of sustaining routine childhood immunisation on only the child deaths averted 
from measles outbreaks during the COVID-19 risk period. We assumed that contact-reducing interventions flattened 
the outbreak curve during the COVID-19 risk period, that 60% of the population will have been infected by the end of 
that period, that children can be infected by either vaccinators or during transport, and that upon child infection the 
whole household will be infected. Country-specific household age structure estimates and age-dependent infection-
fatality rates were applied to calculate the number of deaths attributable to the vaccination clinic visits. We present 
benefit–risk ratios for routine childhood immunisation, with 95% uncertainty intervals (UIs) from a probabilistic 
sensitivity analysis.
Findings In the high-impact scenario, for every one excess COVID-19 death attributable to SARS-CoV-2 infections 
acquired during routine vaccination clinic visits, 84 (95% UI 14–267) deaths in children could be prevented by 
sustaining routine childhood immunisation in Africa. The benefit–risk ratio for the vaccinated children is 
85 000 (4900–546 000), for their siblings (<20 years) is 75 000 (4400–483 000), for their parents or adult carers (aged 
20–60 years) is 769 (148–2700), and for older adults (>60 years) is 96 (14–307). In the low-impact scenario that 
approximates the health benefits to only the child deaths averted from measles outbreaks, the benefit–risk ratio to the 
households of vaccinated children is 3 (0–10); if the risk to only the vaccinated children is considered, the benefit–risk 
ratio is 3000 (182–21 000).
Interpretation The deaths prevented by sustaining routine childhood immunisation in Africa outweigh the excess 
risk of COVID-19 deaths associated with vaccination clinic visits, especially for the vaccinated children. Routine 
childhood immunisation should be sustained in Africa as much as possible, while considering other factors such as 
logistical constraints, staff shortages, and reallocation of resources during the COVID-19 pandemic.
Funding Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Vaccines have substantially improved health and reduced 
mortality, particularly among children in low-income 
countries.1–3 Access to vaccines in these countries 
accelerated after the formation of Gavi, the Vaccine 
Alliance, in 2000.4 This access needs to be sustained to 
further advance the public health gains and maintain 
progress towards goals such as the elimination of polio, 
measles, rubella, and maternal tetanus.5 WHO launched 
the Immunization Agenda 2030 strategy in 2020 to 
accelerate progress towards equitable access and use of 
vaccines over the new decade.6 However, ensuring 
everyone has access to immunisation services has been 
challenging, with a quarter of children in the Africa 
region not receiving three doses of diphtheria-tetanus-
pertussis (DTP3) in 2018.7 An additional challenge is 
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posed by the COVID-19 pandemic,8 which has 
necessitated physical distancing measures to mitigate or 
delay the epidemic to avoid health-care systems being 
overwhelmed.9,10
The severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) emerged in December, 2019, when it 
caused cases of COVID-19 in Wuhan, China.11 As of 
July 10, 2020, there were 12 015 193 confirmed cases and 
549 247 confirmed deaths across 216 countries and 
territories.8 All African countries have reported cases of 
COVID-19, with the majority reporting local transmission 
and rapidly rising case numbers.12 The prevention and 
control measures to suppress and mitigate the COVID-19 
outbreak in Africa during the upcoming months will 
place immense pressures on the national health systems 
in their provision of essential health services, including 
the Expanded Programme on Immunization (EPI) and 
routine vaccination of infants.13
On March 26, 2020, WHO and the Pan American 
Health Organization issued guidance on the operation of 
immunisation programmes during the COVID-19 pan-
demic.14,15 The guidance called for temporary suspension 
of mass vaccination campaigns and a benefit–risk 
assessment to decide on conducting outbreak response 
mass vaccination campaigns; routine immuni sation 
programmes were advised to be sustained in places where 
essential health services had operational capacity of 
adequate human resources and vaccine supply, while 
maintaining physical distancing and other infection 
control measures.
Our aim was to compare the health benefits of 
sustaining routine childhood immunisation in Africa 
with the risk of acquiring SARS-CoV-2 infection through 
visiting routine vaccination service delivery points. 
Specifically, we did a benefit–risk analysis of vaccine-
preventable deaths averted by sustaining routine 
childhood immunisation in comparison with excess 
COVID-19 deaths from SARS-CoV-2 infections acquired 
by visiting routine vaccination service delivery points.
Methods 
Assumptions
We assessed the benefit and risk of continued routine 
childhood immunisation during the COVID-19 pan demic 
in all 54 African countries. We focused on the delivery of 
infant immunisation at: (1) 6, 10, and 14 weeks of age for 
diphtheria, tetanus, and pertussis (DTP), hepatitis B, 
Haemophilus influenzae type b, Streptococcus pneumoniae, 
and rotavirus (hereafter called EPI-1); (2) 9 months for 
measles (MCV1), rubella (RCV1), Neisseria meningitidis 
serogroup A, and yellow fever (hereafter called EPI-2); 
and (3) 15–18 months for the second dose of measles 
(MCV2; hereafter called EPI-3). The target age for 
N meningitidis serogroup A routine immunisation varies 
by country and is given along with the first or second dose 
of measles vaccine; it is given at 9 months in Central 
African Republic, Chad, Côte d’Ivoire, Mali, Niger, and 
Sudan, at 15 months in Burkina Faso, and at 18 months in 
Ghana.16 We did not consider BCG or hepatitis B birth 
dose because they are recommended for administration 
shortly after birth and thus were assumed not to require 
an additional vaccination visit, even though home births 
or delayed administration might be common in some 
parts of Africa.
During the period of SARS-CoV-2 circulation, we 
assumed that contact-reducing measures were in place 
Research in context
Evidence before this study
National immunisation programmes globally are at risk of 
disruption due to the severe health system constraints caused by 
the ongoing COVID-19 pandemic and the physical distancing 
measures to mitigate the outbreak. Outbreaks of vaccine-
preventable disease have been observed during previous 
interruptions to routine immunisation services, such as during 
the 2013–16 Ebola outbreak in west Africa, when most health 
resources were shifted towards the Ebola response and decreased 
vaccination coverage led to consequent outbreaks of measles 
and other vaccine-preventable diseases. WHO has recommended 
that countries conduct individual benefit–risk assessments to 
support decision making on sustaining immunisation services 
during the COVID-19 pandemic based on the local transmission 
dynamics of severe acute respiratory syndrome coronavirus 2, 
the epidemiology of vaccine-preventable diseases, and the 
characteristics of their immunisation and health systems. To the 
best of our knowledge, this is the first benefit–risk analysis on 
sustaining routine childhood immunisation in African countries 
during the COVID-19 pandemic.
Added value of this study
We estimated the benefit–risk ratio by comparing the deaths 
prevented by sustaining routine childhood immunisation for 
diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae 
type b, Streptococcus pneumoniae, rotavirus, measles, Neisseria 
meningitidis serogroup A, rubella, and yellow fever with the 
excess COVID-19 deaths associated with vaccination clinic visits. 
The benefit of routine childhood immunisation programmes in 
all 54 African countries was found to be greater than the 
COVID-19 risk associated with these vaccination clinic visits. 
Implications of all the available evidence
Routine childhood immunisation programmes should be 
safeguarded for continued service delivery and prioritised for 
the prevention of infectious diseases, as much as is logistically 
possible, as part of delivering essential health services during 
the COVID-19 pandemic in Africa. The current immunisation 
service models will require adaptation, including physical 
distancing measures, personal protective equipment, and good 
hygiene practices for infection control at the vaccination clinics. 
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and that although those measures did not contain the 
outbreak, they did substantially flatten the epidemic 
curve. However, with gradual easing of interventions and 
in the absence of a vaccine, we assumed that SARS-CoV-2 
transmission will infect around 60% of the population. 
In both alternative scenarios (uncontrolled epidemic or 
successful containment), sustaining vaccination as far as 
possible would be the obvious choice because doing so 
would not substantially affect the risk of SARS-CoV-2 
infection.
We assumed that the risk from COVID-19, and hence 
the potential disruption to health services, including 
routine childhood vaccination, lasts for 6 months. The 
main analyses consider the impact of continuation of 
all five immunisation clinic visits in comparison with 
the risk of COVID-19 disease in the vaccinated child’s 
household as a result of attending the vaccine clinic, 
tracking the health benefits from immunisation among 
the vaccinated children until 5 years of age.
Benefits of sustained routine childhood immunisation
We used the health impact estimates provided by Li and 
colleagues3 for vaccines against hepatitis B, H influenzae 
type b, measles, N meningitidis serogroup A, S pneumoniae, 
rotavirus, rubella, and yellow fever. For the health impact 
of vaccines against diphtheria, tetanus, and pertussis, we 
calculated basic estimates for the annual number of 
deaths averted per 1000 vaccinated children by DTP3 in 
Africa, on the basis of global annual DTP3 vaccine 
impact estimates from 1980 to 2013.17 We did not include 
polio-vaccine-preventable mortality in our estimates. 
Antigen-specific estimates of per-capita deaths averted by 
vaccination were unavailable for nine countries (Algeria, 
Botswana, Equatorial Guinea, Gabon, Libya, Mauritius, 
Namibia, Seychelles, and South Africa) and were approxi-
mated to the mean estimates of other countries with 
available data. Country-specific and antigen-specific levels 
of routine vaccination coverage were assumed to be the 
same in 2020 as in 2018.
The child deaths averted by routine vaccination during 
a 6-month suspension period of immunisation are the 
product of country-specific and antigen-specific estimates 
of per-capita deaths averted by vaccination from the time 
of vaccination until 5 years of age,3,17 country-specific 
population estimates of the vaccinated cohort,18 country-
specific and antigen-specific official country reported 
estimates of vaccination coverage,19 and the suspension 
period of immunisation.
We considered a high-impact scenario and a low-
impact scenario for approximating the effects of 
sustaining routine childhood immunisation during the 
COVID-19 pandemic. In the high-impact scenario, we 
approximated the impact of sustaining routine childhood 
immunisation with use of the estimates of vaccination 
impact for a 6-month cohort in 2020. Hence, this scenario 
assumes that the suspension of immunisation will result 
in a cohort of unvaccinated children who have the same 
risk of disease as children in a completely unvaccinated 
Vaccination schedule Deaths averted by vaccination 
(95% UI)
Excess COVID-19 deaths 
(95% UI)
Benefit–risk ratio 
(95% UI)
Diphtheria 6, 10, 14 weeks 12 944 (10 180–16 539) 5674 (846–16 830) 2 (0–7)
Tetanus 6, 10, 14 weeks 69 254 (54 268–87 343) 5674 (846–16 830) 12 (2–39)
Pertussis 6, 10, 14 weeks 271 422 (207 238–344 147) 5674 (846–16 830) 48 (8–155)
Hepatitis B 6, 10, 14 weeks 3827 (2578–5826) 5677 (846–16 837) 1 (0–2)
Haemophilus influenzae type b 6, 10, 14 weeks 54 840 (49 521–61 230) 5696 (849–16 896) 10 (2–30)
Streptococcus pneumoniae 6, 10, 14 weeks 46 494 (40 002–55 014) 5052 (752–14 979) 9 (2–29)
Rotavirus 6, 10 weeks 10 666 (9578–11 890) 2391 (364–7221) 4 (1–14)
Measles (MCV1) 9 months 194 388 (181 469–209 379) 1896 (228–5778) 103 (16–332)
Rubella (RCV1) 9 months 1147 (738–1679) 744 (85–2264) 2 (0–5)
Neisseria meningitidis serogroup A 9 months 460 (335–665) 280 (34–856) 2 (0–6)
Yellow fever 9 months 23 345 (17 426–30 929) 875 (100–2664) 27 (4–87)
Measles (MCV2; EPI-3) 15–18 months 10 282 (9354–11 237) 751 (81–2277) 14 (2–45)
EPI-1* 6, 10, 14 weeks 471 068 (406 088–548 290) 5696 (849–16 896) 82 (14–261)
EPI-2† 9 months 219 726 (204 572–235 744) 1896 (228–5778) 116 (18–374)
EPI‡ 6, 10, 14 weeks; 9 months; 
15–18 months
701 828 (635 416–782 050) 8341 (1280–25 029) 84 (14–267)
The benefit–risk ratio estimates (median estimates and 95% UIs) show the child deaths averted by sustaining routine childhood immunisation in Africa per COVID-19 death 
attributable to excess severe acute respiratory syndrome coronavirus 2 infections acquired through visiting routine vaccination service delivery points. Note that the vaccine-
preventable death estimates are vaccine antigen-specific, whereas the excess deaths are dependent on the number of required visits. Because vaccination visits EPI-1 and 
EPI-2 group the delivery of several vaccines, these have a higher benefit–risk ratio than that for individual antigens. EPI=Expanded Programme on Immunization. 
UI=uncertainty interval. *EPI-1 includes three-dose vaccinations for diphtheria, tetanus, and pertussis, hepatitis B, Haemophilus influenzae type b, and Streptococcus 
pneumoniae, and vaccination for rotavirus. †EPI-2 includes the first dose of vaccination for measles (MCV1) and rubella (RCV1) and vaccination for Neisseria meningitidis 
serogroup A and yellow fever. ‡EPI includes all vaccinations in EPI-1 and EPI-2, as well as the second dose for measles (MCV2; EPI-3).
Table 1: Vaccine antigen-specific benefits and risks of sustaining routine childhood immunisation in Africa during the COVID-19 pandemic
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population, and their vulnerability persists until they are 
5 years old (ie, no catch-up campaign conducted at the 
end of the SARS-CoV-2 outbreak). Because of herd 
protection and likely catch-up activities at the end of a 
potential disruption of immunisation services, this high-
impact scenario is likely to overestimate the negative 
impact of suspending immunisation services for a short 
period.
By contrast, in the low-impact scenario, we attempted to 
estimate a lower bound for the expected number of deaths 
due to disruptions to routine childhood immunisation 
services. We assumed that, in the absence of immuni-
sation, herd immunity would protect children missing 
vaccination for all diseases with the exception of measles, 
and that vaccination through catch-up campaigns would 
close measles immunity gaps immediately following the 
6-month COVID-19 disruption period. This scenario was 
implemented as illustrated by the following example. In a 
country with 80% routine measles vaccine coverage, the 
interepidemic period of measles outbreaks is about 
4 years.20 The suspension of the routine vaccination pro-
gramme for 6 months would correspond to an accumu-
lation of susceptible individuals equivalent to 30 months 
in normal times, thus shrinking the interepidemic period 
to 2 years. In the absence of supplementary immunisation 
activities, this shorter period would yield a 25% chance 
that an outbreak would start during the 6 months of 
suspension. Furthermore, the physical distancing inter-
ventions in place to mitigate COVID-19 risk could 
decrease that outbreak probability by an additional 50%. 
Thereby, there is a 12·5% (25% × 50%) chance of a 
measles outbreak during the 6-month suspension period. 
In this low-impact scenario, the health impact of routine 
childhood immunisation includes only a 12·5% pro-
portion of the health benefits derived from measles 
vaccination, while excluding the health impact of the 
other vaccines.21
Supplementary immunisation activities for 17 African 
countries in 2020 are either currently postponed or of 
unknown status and reflect a higher risk of measles 
outbreaks in comparison with the low-impact scenario 
used in this study.22 If routine childhood immunisation 
programmes are also suspended, the further decline in 
vaccination coverage enhances the risk of measles 
outbreaks in the near future.
Excess risk of COVID-19 disease
We assume that in the coming months African countries 
will experience SARS-CoV-2 spread similar to that 
observed in non-African countries affected earlier in the 
pandemic, which were unable to contain the virus. We 
assume that the warmer climates in Africa will not 
notably reduce the transmissibility of SARS-CoV-2.23,24
The risk of COVID-19 depends on exposure probability 
to SARS-CoV-2 and progression to disease. For this 
analysis, we consider only the infection-fatality risk for 
COVID-19 and ignore other potentially severe health 
Deaths averted by 
vaccination (95% UI)
Excess COVID-19 
deaths (95% UI)
Benefit–risk ratio 
(95% UI)
Algeria 18 164 (11 750–28 146) 268 (29–794) 69 (10–234)
Angola 26 156 (18 377–36 792) 146 (24–434) 180 (28–598)
Benin 7285 (4817–11 246) 78 (8–228) 95 (14–311)
Botswana 989 (646–1511) 15 (2–43) 70 (11–233)
Burkina Faso 14 103 (9626–20 955) 180 (20–534) 80 (13–259)
Burundi 8640 (5946–12 784) 79 (13–238) 110 (19–367)
Cameroon 13 031 (8735–19 862) 176 (20–519) 75 (11–249)
Cape Verde 148 (85–251) 3 (0–9) 52 (6–176)
Central African Republic 2353 (1585–3513) 20 (3–60) 119 (21–392)
Chad 9016 (5998–13 984) 98 (10–288) 94 (11–310)
Comoros 420 (267–661) 7 (1–22) 58 (7–197)
Congo (Brazzaville) 3370 (2366–4919) 21 (3–63) 160 (19–515)
Côte d’Ivoire 19 401 (12 712–28 863) 194 (20–571) 102 (16–339)
Democratic Republic of the 
Congo
61 538 (41 399–92 956) 563 (88–1674) 111 (18–371)
Djibouti 273 (173–435) 5 (1–14) 58 (8–203)
Egypt 24 593 (11 655–48 336) 412 (54–1221) 60 (6–216)
Equatorial Guinea 360 (231–564) 4 (0–13) 83 (12–273)
Eritrea 2103 (1380–3152) 29 (4–88) 74 (9–245)
eSwatini 346 (180–603) 9 (1–28) 38 (4–136)
Ethiopia 60 854 (38 286–95 401) 866 (100–2558) 73 (10–243)
Gabon 866 (554–1360) 8 (1–25) 105 (17–358)
Gambia 2208 (1560–3107) 39 (6–117) 58 (10–189)
Ghana 18 589 (12 358–26 534) 219 (32–658) 86 (14–281)
Guinea 9307 (6339–13 372) 121 (17–362) 78 (11–255)
Guinea-Bissau 1355 (960–1912) 12 (1–36) 113 (18–379)
Kenya 20 030 (12 691–31 736) 241 (38–720) 86 (13–292)
Lesotho 829 (536–1263) 15 (2–43) 57 (8–195)
Liberia 3965 (2913–5689) 34 (4–101) 118 (17–381)
Libya 2323 (1517–3463) 34 (5–103) 70 (11–230)
Madagascar 14 293 (9228–22 263) 136 (21–405) 107 (16–359)
Malawi 8923 (5398–14 737) 131 (20–393) 69 (10–232)
Mali 13 302 (9259–18 971) 144 (17–426) 94 (14–308)
Mauritania 2720 (1905–4119) 30 (3–90) 91 (13–310)
Mauritius 260 (177–391) 4 (1–11) 71 (11–230)
Morocco 7273 (3698–13 837) 221 (26–657) 34 (4–124)
Mozambique 20 206 (13 487–30 366) 208 (33–624) 98 (14–317)
Namibia 1179 (768–1812) 19 (2–56) 63 (9–214)
Niger 21 835 (15 854–30 867) 262 (30–776) 85 (13–278)
Nigeria 89 167 (61 172–133 594) 942 (98–2773) 96 (16–316)
Rwanda 8061 (5274–12 053) 87 (14–260) 94 (15–318)
São Tomé and Príncipe 120 (72–186) 1 (0–4) 91 (12–296)
Senegal 11 306 (7856–15 866) 250 (37–758) 46 (6–154)
Seychelles 34 (23–50) 0 (0–1) 74 (10–245)
Sierra Leone 6891 (5096–9376) 86 (11–256) 81 (12–266)
Somalia 9697 (6695–14 275) 102 (11–300) 96 (16–319)
South Africa 18 844 (12 575–28 607) 310 (36–920) 62 (10–209)
South Sudan 3176 (1716–5251) 34 (5–102) 93 (11–322)
Sudan 22 338 (13 975–34 110) 334 (49–1003) 68 (10–231)
Tanzania 36 630 (23 570–56 036) 584 (87–1757) 64 (8–209)
Togo 4933 (3206–7819) 56 (6–164) 90 (13–307)
(Table 2 continues on next page)
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outcomes. We model the additional SARS-CoV-2 exposure 
risk for the vaccinated child, their carer, and household 
members as a result of contact with the vaccinator and 
other community members during travel to the vaccine 
clinic. The simulation parameters for SARS-CoV-2 
infection dynamics were based on the Reed-Frost epidemic 
model (appendix 1 p 2).25 The COVID-19 risk model is 
described in more detail in appendix 1 (pp 3–4). We used 
the country-specific household age composition to 
approximate the age distribution in households at risk of 
SARS-CoV-2 infection, given that one of the household 
members is a child who has been vaccinated (appendix 1 
p 5).26 We applied age-stratified infection-fatality risk for 
SARS-CoV-2 using estimates obtained from reported 
cases and their severity in China, in combination with the 
proportion of asymptomatic infections estimated among 
inter national residents repatriated from China.27 For 
children (<20 years), we used the reported risk for ages 
0–9 years; for adults (20–59 years), we used the reported 
risk for ages 30–39 years; and for older adults (>60 years), 
we used the reported risk for ages 60 years and older 
(appendix 1 p 5).
Sensitivity analysis
We did a probabilistic sensitivity analysis by conducting 
4000 simulation runs to account for the uncertainty 
around the parameters governing the SARS-CoV-2 infec-
tion model, as well as the reported uncertainty ranges for 
the infection fatality rate estimates (modelled using a 
γ distribution) and the vaccine-preventable mortality 
estimates (modelled using a log-normal distribution), and 
assessed their impact on our findings. We constructed a 
tornado diagram using a multivariate Poisson regression 
model  fitted to the estimated posterior distribution of the 
benefit–risk ratio using our model input parameters as 
predictors, and treating total deaths averted by childhood 
immunisation as a single variable.
The program code and data for the benefit–risk analysis 
in this study are accessible online. All analyses were 
done using R 3.6.0.28 All data were from secondary 
sources in the public domain, and ethics approval was 
thereby not required.
Role of the funding source 
The funders were involved in study design, data 
collection, data analysis, data interpretation, writing of 
the report, and the decision to submit for publication. All 
authors had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
In the high-impact scenario, we estimate that the current 
routine childhood immunisation programme (DTP, 
hepatitis B, H influenzae type b, S pneumoniae, rotavirus, 
measles, rubella, N meningitidis serogroup A, and yellow 
fever) in Africa during a 6-month period in 2020 will 
prevent around 702 000 (95% uncertainty interval 
[UI] 635 000–782 000) deaths in children from the time of 
vaccination until they are 5 years old (table 1). About a 
third of averted deaths are attributable to measles and 
another third to pertussis. Immunisation during the 
three EPI-1 visits (three-dose vaccinations for DTP, 
hepatitis B, H influenzae type b, and S pneumoniae, and 
vaccination for rotavirus) could prevent approximately 
471 000 (406 000–548 000) deaths. Immuni sation during 
See Online for appendix 1
For the program code and data 
used in this study see 
https://github.com/vaccine-
impact/epi_covid
Deaths averted by 
vaccination (95% UI)
Excess COVID-19 
deaths (95% UI)
Benefit–risk ratio 
(95% UI)
(Continued from previous page)
Tunisia 1854 (723–3626) 54 (8–163) 35 (3–128)
Uganda 20 906 (12 346–34 358) 246 (39–734) 87 (12–299)
Zambia 11 042 (7453–16 810) 121 (19–361) 93 (13–312)
Zimbabwe 7759 (5269–11 124) 94 (14–284) 83 (12–278)
The benefit–risk ratio estimates (median estimates and 95% UIs) show the child deaths averted by sustaining routine 
childhood immunisation in the African countries per COVID-19 death attributable to excess severe acute respiratory 
syndrome coronavirus 2 infections acquired through visiting routine vaccination service delivery points. The combined 
impact of routine childhood immunisation is shown, including all vaccinations in EPI-1, EPI-2, and EPI-3. 
EPI=Expanded Programme on Immunization. UI=uncertainty interval. 
Table 2: Benefits and risks of sustaining routine childhood immunisation at the national level
Figure 1: Benefit–risk ratios for sustaining routine childhood immunisation during the COVID-19 pandemic in 
Africa
In this scenario, we assume that the suspension of immunisation will result in a cohort of unvaccinated children 
who have the same risk of disease as children in a completely unvaccinated population, and their vulnerability 
persists until they are 5 years old (ie, no catch-up campaigns). A benefit–risk ratio greater than 1 indicates in favour 
of sustaining the routine childhood immunisation programme. Countries shaded in grey had missing data.
0·1
1·0
10·0
100·0
Benefit–risk ratio
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the EPI-2 visit (first dose of vaccination for measles [MCV1] 
and rubella [RCV1] and vaccination for N meningitidis 
serogroup A and yellow fever) is estimated to prevent 
around 220 000 (205 000–236 000) deaths, and immuni-
sation during the EPI-3 visit (second dose for measles 
[MCV2]) to prevent 10 300 (9400–11 200) deaths among 
children until they are 5 years old. A third of the deaths 
prevented by routine childhood vaccination are predicted 
to be in Nigeria, Democratic Republic of the Congo, 
Ethiopia, and Tanzania (table 2).
We estimate that the three immunisation visits for EPI-1 
add a total of 2·4% (0·7–7·6) and each immuni sation visit 
of EPI-2 and EPI-3 adds 0·8% (0·2–2·7) to the probability 
of excess SARS-CoV-2 infection in the household. As a 
result, continuation of routine childhood immunisation 
in Africa could lead to 8300 (1300–25 000) excess deaths 
attributable to additional SARS-CoV-2 infections asso-
ciated with the immunisation visits of children. About 
eight (0–40) of these are expected to be among the 
vaccinated children, nine (0–45) among their siblings, 
914 (83–2800) among their parents or adult carers, and 
7300 (852–22 300) among older adults in the household.
For every one excess COVID-19 death attributable to 
additional household exposure to SARS-CoV-2 infection 
due to routine childhood immunisation visits in this high-
impact scenario, we estimate that the routine childhood 
immunisation programme would prevent 84 (95% UI 
14–267) deaths in children up to 5 years of age in Africa 
(table 1). The benefit of the three EPI-1 immunisation 
visits in early infancy and the visit for EPI-2 at 9 months 
was 82 (14–261) and 116 (18–374) deaths averted among 
children per excess COVID-19 death, respectively. The 
incremental benefit of the second dose of measles 
vaccination during the EPI-3 visit at 15–18 months was 
14 (2–45) deaths averted among children per excess 
COVID-19 death. Almost 90% of the excess COVID-19 
risk is due to the high fatality rate among older adults 
(>60 years; 96 [14–307] deaths averted per excess COVID-19 
death). If only the risk to vacci nated children is considered, 
the benefit–risk ratio is substantially higher at 85 000 
(4900–546 000) deaths averted per excess COVID-19 death 
(appendix 1 p 6). The benefit–risk ratio for the siblings 
(<20 years) of vaccinated children is 75 000 (4400–483 000), 
and for their parents or adult carers (20–60 years) is 
769 (148–2700). Our findings were largely similar across 
countries (figure 1, table 2; appendix 1 pp 7–9, appendix 2). 
Country-specific benefit–risk ratios for EPI-1, EPI-2, and 
EPI-3 are presented in appendix 1 (pp 10–12). The overall 
benefit–risk ratio of sustaining routine childhood 
immunisation ranged from 34 (4–124) in Morocco to 
180 (28–598) in Angola, and the number of child deaths 
averted through vaccination substantially exceeded the 
number of excess COVID-19 deaths for all 54 countries in 
Africa.
In the low-impact scenario, which approximates the 
health benefits to only the child deaths averted from 
measles outbreaks, the benefit–risk ratio to the house-
holds of vaccinated children is 3 (0–10). If the risk to only 
the vaccinated children is considered, the benefit–
risk ratio is 3000 (182–21 000). Even with these highly 
conservative assumptions, the benefit–risk ratio for most 
countries in Africa is greater than 1, indicating in favour 
of sustaining the routine childhood immunisation 
programme during the COVID-19 pandemic (figure 2). 
Tunisia, eSwatini, Morocco, and Egypt have benefit–risk 
ratios of less than 1 because measles vaccination impact 
is lower in these countries compared with other countries 
in Africa (appendix 2). Although the lower bounds of 
the uncertainty intervals of the benefit–risk ratios at the 
household level are less than 1 for some countries, the 
lower bounds of the benefit–risk ratios for the vaccinated 
children are greater than 1 for all countries.
We evaluated the contribution of the uncertainty in the 
model parameters to the uncertainty in the benefit–risk 
ratio estimates (figure 3). The main factors affecting our 
estimates of the benefit–risk ratio were the average 
number of contacts of the child and their carer during a 
visit to the vaccine clinic, the average number of 
transmission-relevant contacts of a community member 
per day and therefore the risk for transmission given a 
potentially infectious contact, and the infection fatality 
Figure 2: Benefit–risk ratios of sustaining routine childhood vaccination, with a minimal chance of a measles 
outbreak and no other vaccine-preventable outbreaks, during the COVID-19 pandemic in Africa
In this scenario, we assumed that, in the absence of immunisation, herd immunity would protect children missing 
vaccination for all diseases except measles. We assumed that the chance of a measles outbreak during the 6-month 
suspension of immunisation was 12·5%, and no other vaccine-preventable disease outbreaks occurred. Countries 
shaded in grey had missing data.
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Articles
www.thelancet.com/lancetgh   Published online July 17, 2020   https://doi.org/10.1016/S2214-109X(20)30308-9 7
rate for older adults (>60 years) with SARS-CoV-2 
infection.
Discussion
Our analysis suggests that the benefit of sustaining 
routine childhood immunisation in Africa far outweighs 
the excess risk of COVID-19 deaths due to the additional 
risk of SARS-CoV-2 infection during the child’s 
vaccination visit, particularly for the vaccinated children. 
This finding reinforces the guidance issued by WHO14 
and a statement from the Measles & Rubella Initiative29 
which assert that routine childhood immunisation 
programmes should be sustained if essential health 
services have operational capacity of adequate human 
resources and vaccine supply, while maintaining physical 
distancing and other infection control measures to 
ensure the safety of communities and health workers.
We based our analyses on model-based country-specific 
and antigen-specific vaccine impact estimates in low-
income and middle-income countries for 2020.3,17 There 
is considerable uncertainty regarding the impact of 
suspending immunisation activities for a period of about 
6 months and whether a timely and high-coverage catch-
up campaign can be conducted soon after. Therefore, we 
presented two extreme scenarios, a high-impact scenario 
and a low-impact scenario, to evaluate the potential 
benefits of sustaining routine childhood vaccination.
In the high-impact scenario, we approximated the 
impact of sustained routine childhood immunisation with 
the estimates of vaccination impact for a 6-month cohort 
in 2020. This is a basic estimate of the likely impact, 
which, in reality, is also governed by herd protection and 
physical distancing. Although pathogen resurgence will 
happen gradually due to herd protection from the rest of 
the population and potentially only once physical 
distancing is lifted, this could be counterbalanced by 
unvaccinated children of this and other cohorts continuing 
to be at risk of disease beyond the 6-month period. In the 
presence of physical distancing measures, the exposure 
to non-coronavirus pathogens will also probably be 
reduced, but those who remain susceptible as a result of 
immunisation service suspension could get infected once 
physical distancing measures are relaxed. In the low-
impact scenario, we approximated the impact of sus-
taining vaccination by the number of child deaths as a 
result of potential measles outbreaks during the COVID-19 
risk period, assuming that catch-up campaigns will be 
delivered at the end of the COVID-19 risk period. We 
showed that, in both scenarios, continuation of routine 
childhood immuni sation is beneficial and out weighs the 
excess risk of COVID-19 deaths due to the additional risk 
for SARS-CoV-2 infections during the immunisation 
visits, especially for the vaccinated children. Of note, 
SARS-CoV-2 infections acquired by the vaccinated 
children or their adult carers and parents at the vaccination 
clinics pose a risk primarily for the older adults in their 
households. This finding highlights the importance of 
shielding older adults to lower their risk of acquiring 
SARS-CoV-2 infections, while allowing children in their 
households to benefit from routine vaccination to lower 
their risk of acquiring vaccine-preventable infectious 
diseases.30
Although the young age demographic in Africa might 
mitigate some of the COVID-19 disease burden, infection 
fatality rates in Africa could be substantially higher 
because of the prevalence of likely risk factors, including 
HIV, tuberculosis, and malnutrition, and poor access to 
antibiotics to reduce the risk of bacterial co-infections in 
some parts of Africa. In the event that infection fatality 
rates in Africa turn out to be higher than elsewhere, then 
the estimated benefit–risk ratio would be reduced. 
However, our uncertainty analysis shows that although 
the uncertainty of the COVID-19 infection fatality rate is a 
key factor in the overall uncertainty of our estimates, even 
at the upper mortality bounds, sustaining routine child-
hood vaccination is beneficial. Furthermore, the effects 
of a potentially higher COVID-19 case-fatality ratio in 
Africa might be balanced by a higher case-fatality ratio of 
measles and the other vaccine-preventable diseases in 
times when the health-care system is stretched, treatment 
supplies are disrupted, and access to drugs such as 
vitamin A and antibiotics is reduced.
Our findings were similar across countries with 
respect to the benefit–risk ratios, indicating in favour of 
sustaining the childhood immunisation programmes 
during the COVID-19 pandemic in Africa. Although 
there will be heterogeneity in the implementation of 
and compliance with prevention and control measures 
for COVID-19 in different countries, the benefits of 
sustaining childhood immunisation far outweigh the 
Figure 3: Sensitivity analysis for uncertainty in the benefit–risk ratio estimates
The tornado diagram was constructed using a multivariate Poisson regression model fitted to the estimated 
posterior distribution of the benefit–risk ratio using our model input parameters as predictors, and treating total 
deaths averted by childhood immunisation as a single variable. SARS-CoV-2=severe acute respiratory syndrome 
coronavirus 2.
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risks of excess SARS-CoV-2 infections acquired during 
the vaccination visits, especially for the vaccinated 
children.
Because of high transmissibility of measles, routine 
childhood immunisation coverage in many countries is 
insufficient to prevent outbreaks. To aid routine vacci-
nation coverage, supplementary immunisation activities 
are conducted regularly, and many were scheduled for 
2020, at a time shortly before sufficient accumulation of 
susceptible children had built up to trigger measles 
outbreaks.31 Many of these supplementary immunisation 
activities have been postponed to reduce the risk of 
SARS-CoV-2 infections during mass vaccination,14,31 
further enhancing the likelihood and impact of measles 
outbreaks. Because they are timed at specific intervals 
to avoid outbreaks, our low-impact scenario is likely to 
underestimate the risk of an outbreak occurring due to 
suspension of routine childhood immunisation. Although 
this risk might be mitigated in part by physical distancing 
in response to COVID-19, the risk of outbreaks will 
be concentrated in the periods when interventions are 
gradually lifted and before a catch-up campaign can be 
done.
We did a probabilistic sensitivity analysis to assess the 
impact of parameter uncertainty on the estimated 
benefit–risk ratios. We found that the biggest contributors 
to the uncertainty around the benefit of sustaining 
routine childhood immunisation during the COVID-19 
pandemic in Africa were the transmission probability 
and the number of contacts during a vaccination visit. 
These factors highlight the need for personal protective 
equipment for vaccinators, the need to implement 
physical distancing measures, including the avoidance of 
crowded waiting rooms for vaccination visits, and the 
importance of good hygiene practices to reduce the risk 
of SARS-CoV-2 acquisition and transmission at the 
vaccination clinics. Although the implementation of 
some of these infection prevention and control measures 
in many African countries will be challenging due to 
resource constraints, the risks can be minimised and the 
benefits can be enhanced by providing immunisation 
bundled with other health services, thereby reducing the 
number of physical touch points with the health system.
Our study has limitations and other factors must 
be considered during strategic decision making on 
sustaining routine childhood immunisation in African 
countries during the COVID-19 pandemic. These factors 
include logistical constraints of vaccine supply and delivery 
cold-chain problems caused by the COVID-19 pandemic, 
reallocation of doctors and nurses to other prioritised 
health services, health-care staff shortages caused by 
SARS-CoV-2 infections among the staff, staff shortages 
because of ill-health or underlying health conditions that 
put staff members at increased risk for severe COVID-19 
disease, logistical and resource constraints for imple-
mentation of SARS-CoV-2 infection prevention and control 
measures at the vaccination service delivery points, and 
decreased demand for vaccination arising from commu-
nity reluctance to visit vaccination clinics for fear of 
contracting SARS-CoV-2 infection or broader distrust 
of vaccines fuelled by COVID-19-related rumours and 
misinformation. The risk of SARS-CoV-2 infection for the 
vaccinated children and health-care staff involved in 
immunisation activities, as well as to their households 
and onward SARS-CoV-2 transmission into the wider 
community, should also be considered (appendix p 13).
Although we have estimated benefit–risk ratios on the 
basis of deaths averted, this analysis could be extended to 
estimate benefit–risk ratios on the basis of disability-
adjusted life-years averted or quality-adjusted life-years 
gained. Because the deaths averted by vaccination are 
primarily among children younger than 5 years and 
deaths caused by COVID-19 are primarily among older 
adults, the benefit–risk ratios will be relatively higher 
using disability-adjusted life-years averted or quality-
adjusted life-years, and will be more favourable towards 
sustaining routine childhood immunisation programmes 
during the COVID-19 pandemic in Africa.
In conclusion, routine childhood immunisation pro-
grammes should be safeguarded for continued service 
delivery and prioritised for the prevention of infectious 
diseases, as much as is logistically possible, as part of 
delivering essential health services during the COVID-19 
pandemic in Africa.
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